山岡 邦宏. 安永 正浩編集
「自己免疫疾患治療の発展と課題」
自己免疫疾患・AIDSとDDS：免疫異常・免疫不全への新しい挑戦
山岡邦宏. 猿田享男、北村惣一郎監修.
リウマチ性多発筋痛症 単行本「JMEDJ治療法便覧2020-21年度版~専門家による私の治療〜」. 日本医事新報社. 東京.
山岡邦宏.
IgG4関連疾患 今日の治療指針2020年版. 医学書院. 東京.
山岡邦宏. 猿田享男、北村惣一郎監修.
混合性結合組織病 単行本「JMEDJ治療法便覧2019-20年度版~1336専門家による私の治療〜」. 日本医事新報社. 東京.
山岡邦宏.
抗リウマチ薬・生物学的製剤の副作用と対策 今日の治療指針2019年版.
医学書院. 東京.
山岡邦宏.
特集：「膠原病の個別化医療」テーマ：各論「関節リウマチの個別化医療」.
Precision Medicine. 北隆館. 東京. 2019年. 2(1): 19-21頁.
山岡邦宏.
炎症と免疫の制御療法. 北里医学. 2019年. 49：1-7頁
山岡邦宏.
特集：関節リウマチ−治療薬を使いこなす“ワザ−”と“知恵” 抗RANKL抗体.
薬局. 南山堂. 東京. 2019年. 70(5): 53-58頁
山岡邦宏.
特集：関節リウマチ —「真の寛解」と「安全性」を目指す治療— ＜治療＞JAK阻害剤.
Medical Practic. 文光堂. 東京. 2019年. 36(7)
山岡邦宏.
特集：JAK阻害薬の基礎と臨床 サイトカインシグナル伝達におけるJAK-STATの役割.
リウマチ科. 科学評論社. 東京. 2019年. 62(1)
全身性エリテマトーデス診療ガイドライン2019, 南山堂, 2019.
山岡邦宏.
Btk阻害薬による自己免疫疾患治療の可能性.
リウマチ科. 科学評論社. 東京. 2018年. 59(4): 449-453頁
山岡邦宏.
連載ハイライトシリーズ ベーシックハイライト.
Keynote R・A. 先端医学社. 東京. 2018年. 6(1): 32-35頁
山岡邦宏.
特集I：間葉系幹細胞移植のupdate テーマ 間葉系幹細胞の関節リウマチ.
臨床免疫・アレルギー科. 科学評論社. 東京. 2018年. 70(1): 12-17頁
山岡邦宏.
特集：内科疾患における生物学的製剤の使い分け ウステキヌマブ.
Modern Physician. 新興医学出版社. 東京. 2018年. 38(9): 963-964頁.
有沼良幸，長谷川靖浩：臨床像：抗M O G 抗体関連疾患－リウマチ性疾患併発例－，CLINICAL NEUROSCIENCE，中外医学社，36巻11号1362-1364頁，2018
Arinuma Y, Hirohata S: Neuropsychiatric Systemic Lupus Erythematosus. p59-76, p113-128, Springer, 2018.
Tamai H., Nishina N., Kikuchi J., Izumi K., Otomo K., Yoshimoto K., Yamaoka K., Yakeuchi T., Kaneko Y.
Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs.
Clim Rheumatol. 42(3):721-730 2023.
Tanaka Y., Nakayamada S., Yamaoka K., Ohmura K., Yasuda S.
Rituximab in the Real-World Treatment of Lupus Nephritis: A Retrospective Cohort Study in Japan.
Mod Rheumatol. 33(1):145-153 2023.
Arinuma Y., Hasegawa Y., Tanaka T., Matsueda Y,. Wada T., Oku K., Yamaoka K.
Correlation between soluble TREM2 and anti-GluN2 antibody in lupus patients with diffuse psychiatric/neuropsychological syndromes.
Rheumatology(Oxford). 62(4):e105-e106 2023
Ishiguro N., Tanaka Y., Matsubara Y., Atsumi T., Amano k., Sugiyama E., Yamaoka K., Winthrop KL., Kivitz A., GerdR., Burmester GR., Gottenberg J-E., Genovese MC., Matzkies F., Guo Y., Jiang D., Bartok B., Pechonkina A., Kondo A., Besuyen R., Takeuchio T.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Mod Rheumatol. 33(1):64-72 2023
Curtis JR., Yamaoka K., Chen Y-H., Bhatt DL., Gunay LM., Sugiyama N., Connell CA., Wang C., Wu J., Menon S., Vranic I., Gómez-Reino JJ.
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Ann Rheum Dis. 82(3):331-343 2023
Kondo J, Oku K., Hasegwa Y., Muramatsu T., Matsueda Y., Arinuma Y., Yamaoka K.
Investigation of the poor prognostic factors for life and functional prognosis in patients with asymptomatic dermatomyositis.
Kitasato Med J. 53: 21-28 2023.
Muramatsu T., Oku K., Ikenoue T., Kondo J., Hasegawa Y., Matsueda Y., Arinuma Y., Yamaoka, K.
Varied risk of developing herpes zoster among molecular targeting therapy in rheumatoid arthritis patients: a single-center study.
Kitasato Med J. 53: 10-20 2023.
Hasegawa Y., Arinuma Y., Muramatsu T., Kondo J., Matsueda Y., Kanayama Y., Ino K.,. Tanaka T., Wada T., Oku K., Yamaoka K. The Pathogenic Role of Lupus-Specific Autoantibodies and Interleukin-6 on Demyelination of the Brainstem and Spinal Cord in Systemic Lupus Erythematosus.
Lupus. 32(3):401-410 2023.
Yamaoka K., Oku K.
JAK inhibitors in rheumatology.
Immunological Medicine. (Online ahead of print.) 1-10 2023.
Kanayama Y., Tono T., Tanaka T., Yamaoka K.
A case of rheumatoid arthritis with bilateral shoulder bursitis accompanied by gas image.
Mod Rheumatol Case Rep. 7(1):14-18 2023.
Raveney BJ., El-Darawish Y., Sato W., Arinuma Y., Yamaoka K,. Hori S., Yamamura T., Oki S.
Neuropilin-1(NRP1) expression distinguishesself-reactive helper T cells in systemic autoimmunedisease.
EMBO Mol Med. 14(10):e15864. doi: 10.15252/emmm.202215864. Epub.
Tanaka Y., Matsubara T., Atsumi T., Amano K., Ishiguro N., Sugiyama E., Yamaoka K., Combe BG,. Kivitz A., Bae S-C., Keystone EC., Nash P., Genovese M., Matzkies F., Bartok B., Pechonkina A., Kondo A., Ye L., Gong Q., Tasset C., Takeuchi T.
Safety and Efficacy of Filgotinib for Japanese Patients with RA and Inadequate Response to MTX: FINCH 1 52-Week Results and FINCH 4 48-Week Results.
Mod Rheumatol. 2022. (in press) doi: 10.1093/mr/roac084.
Atsumi T., Tanaka Y., Matsubara T., Amano K., Ishiguro N., Sugiyama E., Yamaoka K, Westhovens R., Ching D.W.T., Daniel M., Burmester G.R., Genovese MC., Bartok B., Pechonkina A., KondoA., Yin Z., Gong Q., Tasset C., Takeuchi T.
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
Mod Rheumatol. (in press) 2022
Bukhari M., Bergman M., Giles JT., Lozada T., Cush T., Yamaoka K. McKay C., Kavanaugh A.
Safety of jakinibs: lessons from ORAL Surveillance.
Rheumatology(Oxford). 61(11):4223-4225, 2022
Winthrop KL., Nash P., Yamaoka K., Mysler E., Khan N., Camp K L., Song Y., Suboticki J L., Curtis J R .
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Ann Rheum Dis. 81(2): 206-213, 2022.
Winthrop KL., Curtis JR., Yamaoka K., Lee EB. ,Hirose T., Rivas JL., Kwok K., Burmester GR.
Clinical management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis receiving tofacitinib treatment.
Rheumatol Ther. 9(1):243-263,2022.
Tanaka Y., Matsubara T., Atsumi T., Amano K., Ishiguro N., Sugiyama E., Yamaoka K., Combe B G., Kivitz A., Bae S-C., Keystone E C., Nash P., Matzkies F., Bartok B., Pechonkina A., Kondo A., Ye L., Guo Y., Tasset C, Sundy J S., Takeuchi T.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Mod Rheumatol. 28;32(2):263-272, 2022.
Atsumi T., Tanaka Y., Matsubara T., Amano K., Ishiguro N., Sugiyama E., Yamaoka K., Westhovens R., Rigby F.C.W., van der Heijde D., Ching D.W.T., Messina OD., Landewé R.B.M., Burmester GR., Bartok B., Pechonkina A., Kondo A., Yin Z., Guo Y., Tasset C., Sundy JS., Takeuchi T.
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis who are naïve to methotrexate: Subpopulation analyses of the interim data of a global Phase 3 study (FINCH 3).
Mod Rheumatol. 28;32(2):273-283, 2022.
Takeuchi T., Matsubara T., Atsumi T., Amano K., Ishiguro N., Sugiyama E., Yamaoka K., Genovese MC., Kalunian K., Walker D., Gottenberg JE., Vlam K., Bartok B., Pechonkina A., Kondo A., Gao J., Guo Y., Tasset C., Sundy JS., Tanaka Y.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global Phase 3 study (FINCH 2).
Mod Rheumatol. 5;32(1):59-67 2022.
Abe N., Tarumi M., Fujieda Y., Takahashi N., Karino K., Uchida M., Kono M., Tanaka Y., Hasebe R., Kato M., Amengual O., Arinuma Y., Oku K., Sato W., Tha KK., Yamasaki M., Watanabe M., Atsumi T., Murakami M.
Pathogenic neuropsychiatric effect of stress-induced microglial interleukin 12/23 axis in systemic lupus erythematosus.
Ann Rheum Dis. 81(11):1564-1575 2022.
Ino K., Kinoshita N., Arinuma Y., Matsueda Y., Yamaoka K. Improvements in PET/CT Results and Serum Cytokine Profile of HLA-B52-positive Patients with Takayasu’s Arteritis and Ulcerative Colitis Post-Tofacitinib. Clin Exp Rheumatol. 40(4)849-850, 2022.
Arinuma Y, Hirohata S, Isayama T, Hasegawa Y, Muramatsu T, Kondo J, Kanayama Y, Ino K, Matsueda Y, Oku K, Yamaoka K.
Anti-ribosomal P Protein Antibodies in Patients with Systemic Lupus Erythematosus is Associated with Hyperferritinemia.
Int J Rheum Dis. doi: 10.1111/1756-185X.14245. (in press) 2021.
Tono T, Kikuchi H, Sawada T, Takeno M, Nagahuchi H, Kirino Y, Tanaka Y, Yamaoka k, Hirohata S.
Clinical features of Behçet’s disease patients with joint symptoms in Japan: a national multicenter study.
Mod Rheumatol. doi: 10.1093/mr/roab092. (in press) 2021.
Winthrop K L, Nash P, Yamaoka K, Mysler E, Khan N, Camp K L, Song Y, Suboticki J L, Curtis J R .
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-220822 (in press) 2021.
Arinuma Y, Asakura H, Yamaoka K.
Reversible basal ganglia lesions in a patient with systemic lupus erythematosus.
Rheumatology(Oxford). doi: 10.1093/rheumatology/keab621. (in press) 2021.
Narisawa M, Kubo S, Okada Y, Yamagata K, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y.
Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability.
Bone. 142:115616 Epub 2021..
Murata O, Suzuki K, Takeuchi T, Sugiura H, Kondo Y, Takeshita M, Koga K, Takiguchi M, Kassai Y, Yasuoka H, Yamaoka K, Morita R, Yoshimura A.
Thymus variants on imaging in patients with rheumatoid arthritis-Clinical and immunological significance.
Rheumatology(Oxford). doi: 10.1093/rheumatology/keab164 (in press) 2021.
Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T.
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Drug Safety. 44(6):711-722.2021
Arinuma Y, Hirohata S, Isayama T, Hasegawa Y, Muramatsu T, Kondo J, Matsueda Y, Yamaoka K.
The clinical significance of anti-Smith antibodies in patients with systemic lupus erythematosus detected by chemiluminescent enzyme immunoassay: a single-center retrospective cohort study.
Kitasato Med J 51(2):109-116, 2021.
Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Genovese MC, Kalunian K, Walker D, Gottenberg JE, Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sundy JS, Tanaka Y.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global Phase 3 study (FINCH 2).
Mod Rheumatol doi: 10.1080/14397595.2020.1859675. (in press) 2021.
Ushikubo M, Saito S, Kikuchi J, Takeshita M, Yoshimoto K, Yasuoka H, Yamaoka K, Seki N, Suzuki K, Oshima H, Takeuchi T.
Milk fat globule epidermal growth factor 8 (MFG-E8) on monocytes is a novel biomarker of disease activity in systemic lupus erythematosus..
LUPUS 30(1):61-69, 2021.
Toshihiro Tono.
Joint Symptoms of Behçet‘s disease.
Japonese Journal of Clinical Medicine. 2021 May 79（6）：867-871.（東野 俊洋. ベーチェット病の関節病変. 日本臨床. 2021 May 79（6）：867-871）
Arinuma Y.
What are the latest clinical findings regarding the association of neurotoxic brain antibodies found in the cerebrospinal fluid in patients with autoimmune disorders?
Curr Opin Neurol.;33(3):347-352. 2020
Tanaka S, Matsueda Y, Kondo J, Yamaoka K.
Effect of Left Ventricular Dysfunction on PAH in Systemic Sclerosis.
Kitasato Med J 50(1): 1-6, 2020
Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman AA, Pangan AL, Asabe S, Kitamura S, Meerwein S, Tanaka Y.
Efficacy and Safety of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (SELECT-SUNRISE): A Placebo-controlled Phase 2b/3 Study.
Rheumatology (Oxford) 59(11):3303-3313, 2020
Arinuma Y, Yamaoka K.
Developmental Process in Diffuse Psychological/ Neuropsychiatric Manifestations of Neuropsychiatric Systemic Lupus Erythematosus.
Immunol Med. 44(1):16-22, 2020
Sasaki T, Yajima T, Shimaoka T, Ogawa S, Saito T, Yamaoka K, Takeuchi T, Kubo M.
Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease.
Int Immunol 32(3):163-174, 2020
Kurihara Y, Maruhashi T, Wada T, Osada M, Oi M., Yamaoka K, Asari Y.
Pancreatitis in a Patient with Severe Coronavirus Disease Pneumonia Treated with Veno-venous Extracorporeal Membrane Oxygenation.
Intern Med. 59(22):2903-2906, 2020
Moridera K, Uchida S, Tanaka S, Menuki K, Utsunomiya H, Yamaoka K, Sonomoto K, Tanaka Y, Sakai A.
Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice.
J Orthop Sci 25(2):331-337, 2020
Hoshiyama T, Wada T, Nihonyanagi S, Kameda R, Yamaoka-Tojo M, Fukuda M, Ako J, Yamaoka K, Takayama Y.
Clinical and Microbiological Features of Asymptomatic SARS-CoV-2 Infection and Mild COVID-19 in Seven Crewmembers of a Cruise Ship.
Intern Med. 59(24):3135-3140, 2020
Wada T, Shimode K, Hoshiyama T, Takayama Y, Yamaoka K.
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.
Front Med (Lausanne). 7:241, eCollection 2020
Muramatsu T, Tono T, Kanayama Y, Hasegawa Y, Kondo J, Hoshiyama T, Wada T, Arinuma Y, Tanaka S, Yamaoka K.
A Case of Anti-MDA5 Antibody-positive Dermatomyositis Developing Reversible Cerebral Vasospasm Syndrome Successfully Treated by Multi-Immunosuppressant Combination Including Mycophenolate Mofetil.
Mod Rheum Case Rep. 5 (1):69-75, 2020
Hasegawa Y, Arinuma Y, Tanaka S, Tono T, Tanaka T, Muramatsu T, Kondo J, Matsueda Y, Hoshiyama T, Wada T, Takayama Y., Yamaoka K.
Haemophilus influenzae Type f Infection in an Adult Patient with Systemic Lupus Erythematosus.
Intern Med. 59(23):3097-3101, 2020
Khatri S, Psaraftis N, Funaro A, Arinuma Y, Fujieda Y, Mader S, Jørgensen CD, Astakhova K.J.
Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens.
Transl Autoimmun. eCollection, 2020
Hasegawa T, Kikuta J, Sudo T, Matsuura Y, Matsui T, Simmons S, Ebina K, Hirao M, Okuzaki D, Yoshida Y, Hirao A, Kalinichenko V, Yamaoka K, Takeuchi T, Ishii M.
Identification of a novel arthritis–associated osteoclast precursor macrophage regulated by FoxM1.
Nat Immunol. 20(12): 1631-1643, 2019.
Moridera K, Uchida S, Tanaka S, Menuki K, Utsunomiya H, Yamaoka K, Sonomoto K, Tanaka Y, Sakai A.
Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice.
J Orthop Sci. 2019 May 6. pii: S0949-2658(19)30120-4.
Yamaoka K.
Tofacitinib for the treatment of rheumatoid arthritis: an update.
Expert Rev Clin Immunol. 2019 Jun;15(6):577-588.
Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O'Shea JJ.
Janus kinases to jakinibs: from basic insights to clinical practice.
Rheumatology (Oxford). 2019 Feb 1;58(Supplement_1):i4-i16.
Kondo Y, Suzuki K, Inoue Y, Sakata K, Takahashi C, Takeshita M, Kassai Y, Miyazaki T, Morita R, Niki Y, Kaneko Y, Yasuoka H, Yamaoka K, Yoshimura A, Takeuchi T
Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis.
Arthritis Res Ther. 2019 Jan 10;21(1):14.
Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich S, Tanaka Y
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Mod Rheumatol. 2019 Sep;29(5):756-766.
Nogi S, Arinuma Y, Komiya A, Hashimoto A, Matsui T, Tohma S.
Clinical Utility of Neutrophil CD64 to Detect Extrapulmonary Tuberculosis in Three Patients with Rheumatoid Arthritis Undergoing Treatment with Biologics.
Case Rep Rheumatol. 2018 Dec 6;2018:2856546.
Matsueda Y, Arinuma Y, Nagai T, Hirohata S.
Synergistic enhancement of production of proinflammatory cytokines of human peripheral blood monocytes by anti-Sm and anti-RNP antibodies.
PLoS One. 2018 Dec 20;13(12):e0209282.
Matsueda Y, Arinuma Y, Nagai T, Hirohata S.
Elevation of serum anti-glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus.
Lupus Sci Med. 2018 Oct 10;5(1):e000281.
Fujieda Y, Mader S, Jeganathan V, Arinuma Y, Shimizu Y, Kato M, Oku K, Minami A, Shimizu C, Yasuda S, Atsumi T.
Clinical significance of anti-DNA/N-methyl-D-aspartate receptor 2 antibodies in de novo and post-steroid cases with neuropsychiatric systemic lupus erythematosus.
Int J Rheum Dis. 2019 Mar;22(3):443-448.
Nakazawa M, Suzuki K, Yasuoka H, Yamaoka K, Takeuchi T
Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies.
Inflamm Regen. 2018 Nov 19;38:20. doi: 10.1186/s41232-018-0079-4.
Nestor J#, Arinuma Y# (#equally contributed), Huerta TS, Kowal C, Nasiri E, Kello N, Fujieda Y, Bialas A, Hammond T, Sriram U, Stevens B, Huerta PT, Volpe BT, Diamond B.
Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors.
J Exp Med. 2018 Oct 1;215(10):2554-2566.
Hakamata J, Kaneko Y, Shimizu M, Yamaoka K, Maruyama J, Takeuchi T, Mochizuki M, Hashiguchi M
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study.
Biol Pharm Bull. 2018;41(9):1414-1422.
Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, Ando T, Nakayama Y, Okuzono Y, Takiguchi M4, Kurisu R, Miyazaki T, Yoshimoto K, Yasuoka H, Yamaoka K, Morita R, Yoshimura A, Toyoshiba H, Takeuchi T
Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission.
Nat Commun. 2018 Jul 16;9(1):2755.
Arinuma Y, Kikuchi H, Hirohata S.
Anti-ribosomal P protein antibodies influence mortality of patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematous involving a severe form of the disease.
Mod Rheumatol. 2019 Jul;29(4):612-618.
Hirohata S, Sakuma Y, Matsueda Y, Arinuma Y, Yanagida T.
Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus.
Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1003-1007.
Sasaki T, Akiyama M, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, Takeuchi T
Risk factors of relapse following glucocorticoid tapering in IgG4-related disease.
Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):186-189.
Arinuma Y
Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus.
Curr Opin Neurol. 2018 Jun;31(3):294-299.
Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T, Mori T, Okamoto S, Kameyama K, Amano K, Tamaru JI, Tokuhira M, Takeuchi T
Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment.
Front Immunol. 2018 Apr 4;9:621.
Akiyama M, Sasaki T, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, Takeuchi T
Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):157-164.
Hakamata J, Hashiguchi M, Kaneko Y, Yamaoka K, Shimizu M, Maruyama J, Takeuchi T, Mochizuki M
Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.
Mod Rheumatol. 2018 Jul;28(4):611-620. doi: 10.1080/14397595.2017.1414765.
Atsumi T, Fujio K, Yamaoka K, Tomobe M, Kuroyanagi K, Kameda H
Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
Mod Rheumatol. 2018 Sep;28(5):780-788.
Hoshiyama T, Matsueda Y, Tono T, Arinuma Y, Nagai T, Hirohata S.
Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes.
Mod Rheumatol. 2018 May;28(3):506-512.
Sakamoto Y, Yamamoto T, Sugano N, Takahashi D, Watanabe T, Atsumi T, Nakamura J, Hasegawa Y, Akashi K, Narita I, Miyamoto T, Takeuchi T, Ikari K, Amano K, Fujie A, Kubo T, Tada Y, Kaneuji A, Nakamura H, Miyamura T, Kabata T, Yamaji K, Okawa T, Sudo A, Ohzono K, Tanaka Y, Yasunaga Y, Matsuda S, Imai Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, Akiyama M, Kubo M, Kamatani Y, Iwamoto Y, Ikegawa S.
Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head.
Sci Rep. 2017 Nov 8;7(1):15035.
Ishioka-Takei E, Yoshimoto K, Suzuki K, Nishikawa A, Yasuoka H, Yamaoka K, Takeuchi T
Increased proportion of a CD38highIgD+ B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjögren's syndrome.
Clin Immunol. 2018 Feb;187:85-91.
Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, Takeuchi T. Microscopic polyangiitis diagnosed by muscle specimen: a case report and literature review.Mod Rheum, online February 5, 2018
Mader S, Jeganathan V, Arinuma Y, Fujieda Y, Dujmovic I, Drulovic J, Shimizu Y, Sakuma Y, Stern JNH, Aranow C, Mackay M, Yasuda S, Atsumi T, Hirohata S, Diamond B
Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
Arthritis Rheumatol. 2018 Feb;70(2):277-286.
Tono T, Aihara S, Hoshiyama T, Arinuma Y, Nagai T, Hirohata S
Effects of CTLA4-Ig on human monocytes.
Inflamm Regen. 2017 Nov 6;37:24.
Arinuma Y, Hasegawa Y, Muramatsu T, Matsueda Y, Yamaoka K
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement.
2019 ACR/ARP Annual Meeting (Atlanta)
Yamaoka K, Tanaka Y, Kameda H, Hendrickson B, Meerwein S, Zhang Y, Takeuchi T
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis.
2019 ACR/ARP Annual Meeting (Atlanta)
山岡邦宏
関節リウマチ治療における骨粗鬆症治療の実際.
第47回日本臨床免疫学会（札幌）
伊野和馬、有沼良幸、下手公介、進藤理沙、金山芳郎、村松匠、長谷川靖浩、田中知樹、星山隆行、東野俊洋、和田達彦、田中住明、山岡邦宏
病理学的検討が可能であった小腸穿孔をきたしたIgG4関連疾患の一例
第47回日本臨床免疫学会(札幌)
長谷川靖浩、有沼良幸、近藤惇一、村松匠、松枝佑、山岡邦宏
全身性エリテマトーデスにおけるベリムマブのヒドロキシクロロキンとの併用及び単剤療法の治療効果
第47回日本臨床免疫学会(札幌)
有沼良幸、長谷川靖浩、村松匠、松枝佑、山岡邦宏
全身性エリテマトーデスにおける抗NMDA受容体サブユニットGluN2抗体の神経精神ループス以外の臓器障害に与える影響
第47回日本臨床免疫学会(札幌)
Hasegawa Y, Arinuma Y, Yamaoka K
Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease.
8th East Asian Group Of Rheumatology 2019 (Seoul)
有沼良幸、諌山 拓也、長谷川靖浩、村松匠、廣畑俊成、山岡邦宏
全身性エリテマトーデスにおける抗リボソームP抗体は臨床的にマクロファージの活性化を引き起こす
第5回骨免疫学会（石垣）
山岡邦宏
関節リウマチにおけるIL-6阻害の有用性
第63回日本リウマチ学会総会（京都）
山岡邦宏
関節リウマチ治療のこれまでとこれから.
第63回日本リウマチ学会総会（京都）
山岡邦宏
JAK阻害剤の基礎と臨床.
第63回日本リウマチ学会総会（京都）
東野俊洋、廣畑俊成、菊地弘敏、沢田哲治、岳野光洋、永渕裕子、桐野洋平、宮川一平、田中良哉、山岡邦宏
関節症状を有するベーチェット病患者の臨床特徴
第63回日本リウマチ学会総会（京都）
村松匠、伊野和馬、長谷川靖浩、近藤惇一、松枝佑、星山隆行、東野俊洋、有沼良幸、和田達彦、永井立夫、田中住明、山岡邦宏
当科における好酸球性多発血管炎性肉芽腫症の臨床像の検討
第63回日本リウマチ学会総会（京都）
伊野和馬、星山隆行、村松匠、長谷川靖浩、近藤惇一、東野俊洋、有沼良幸、永井立夫、田中住明、山岡邦宏
当科での抗MDA5抗体陽性皮膚筋炎患者の臨床像の検討
第63回日本リウマチ学会総会（京都）
近藤惇一、松枝佑、伊野和馬、長谷川靖浩、村松匠、星山隆行、東野俊洋、有沼良幸、和田達彦、永井立夫、田中住明、山岡邦宏
当施設における全身性エリテマトーデス(SLE)に対するヒドロキシクロロキン(HCQ)の治療と検討
第63回日本リウマチ学会総会（京都）
松枝佑、有沼良幸、永井立夫、田中住明、廣畑俊成、山岡邦宏
抗Sm抗体と抗RNP抗体による単球の炎症性サイトカイン産生に対する相乗的増強効果の検討
第63回日本リウマチ学会総会（京都）
有沼良幸、山岡邦宏
脳血管内皮細胞におけるMMP-2発現上昇とclaudin-5減少に対する抗Sm抗体の直接作用.
第63回日本リウマチ学会総会（京都）
田中住明、松枝佑、永井立夫、山岡邦宏
強皮症に合併する境界型肺高血圧の長期予後の検討
第63回日本リウマチ学会総会（京都）
長谷川靖浩、有沼良幸、伊野和馬、近藤惇一、村松匠、松枝佑、星山隆行、東野俊洋、和田達彦、永井立夫、田中住明、山岡邦宏
マクロファージ活性化症候群を呈した全身性エリテマトーデスの臨床的特徴の検討
第63回日本リウマチ学会総会（京都）
山岡邦宏
JAK阻害薬の登場による今後の関節リウマチ治療 JAK阻害薬市販後全例調査と今後の実臨床.
第63回日本リウマチ学会総会（京都）
山岡邦宏
第92回日本整形外科学会学術総会（横浜）
伊野和馬、有沼良幸、村松匠、長谷川靖浩、近藤惇一、松枝佑、星山隆行、東野俊洋、和田達彦、永井立夫、田中住明、山岡邦宏
病理学的検討が可能であった小腸穿孔をきたしたIgG4関連疾患の一例
第29回日本リウマチ学会関東支部学術集会（東京）
山岡邦宏
関節リウマチのエビデンスレビュー
第46回日本臨床免疫学会（軽井沢）
山岡邦宏
関節リウマチの炎症と免疫に対するJAKシグナルの作用.
第46回日本臨床免疫学会（軽井沢）
有沼良幸、諌山拓也、廣畑俊成
全身性エリテマトーデスにおけるステイシアMEBLux™による抗Sm抗体およびMESACUP™による抗リボソームP抗体測定の有用性
第46回日本臨床免疫学会（軽井沢）
Hasegawa Y, Arinuma Y, Ino K, Muramatsu T, Kondo J, Matsueda Y, Hoshiyama T, Tono T, Wada T, Nagai T, Tanaka S
Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease.
2018 ACR/ARP Annual Meeting (Chicago)
